CN101687104A - 包括长春氟宁和曲妥单抗的癌症治疗联合疗法 - Google Patents

包括长春氟宁和曲妥单抗的癌症治疗联合疗法 Download PDF

Info

Publication number
CN101687104A
CN101687104A CN200880017406A CN200880017406A CN101687104A CN 101687104 A CN101687104 A CN 101687104A CN 200880017406 A CN200880017406 A CN 200880017406A CN 200880017406 A CN200880017406 A CN 200880017406A CN 101687104 A CN101687104 A CN 101687104A
Authority
CN
China
Prior art keywords
vinflunine
trastuzumab
carcinoma
cancer
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880017406A
Other languages
English (en)
Chinese (zh)
Inventor
B·文豪威尔
M-C·皮内尔
F-M·德尔加多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Pierre Fabre Medicament SA
Original Assignee
F Hoffmann La Roche AG
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38353425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101687104(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, Pierre Fabre Medicament SA filed Critical F Hoffmann La Roche AG
Publication of CN101687104A publication Critical patent/CN101687104A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200880017406A 2007-05-31 2008-05-29 包括长春氟宁和曲妥单抗的癌症治疗联合疗法 Pending CN101687104A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290679A EP1997534A1 (en) 2007-05-31 2007-05-31 Cancer treatment combination therapy comprising vinflunine and trastuzumab
EP07290679.5 2007-05-31
PCT/EP2008/056620 WO2008145697A1 (en) 2007-05-31 2008-05-29 Cancer treatment combination therapy comprising vinflunine and trastuzumab

Publications (1)

Publication Number Publication Date
CN101687104A true CN101687104A (zh) 2010-03-31

Family

ID=38353425

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880017406A Pending CN101687104A (zh) 2007-05-31 2008-05-29 包括长春氟宁和曲妥单抗的癌症治疗联合疗法

Country Status (18)

Country Link
US (1) US20100196363A1 (enExample)
EP (2) EP1997534A1 (enExample)
JP (1) JP2010528091A (enExample)
KR (1) KR20100017752A (enExample)
CN (1) CN101687104A (enExample)
AR (1) AR066778A1 (enExample)
AU (1) AU2008257555A1 (enExample)
BR (1) BRPI0812280A2 (enExample)
CA (1) CA2689664A1 (enExample)
CL (1) CL2008001589A1 (enExample)
IL (1) IL202393A0 (enExample)
MX (1) MX2009012874A (enExample)
NO (1) NO20093536L (enExample)
RU (1) RU2009146882A (enExample)
TN (1) TN2009000490A1 (enExample)
TW (1) TW200908976A (enExample)
WO (1) WO2008145697A1 (enExample)
ZA (1) ZA200908247B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MY194408A (en) 2011-10-14 2022-11-30 Genentech Inc Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab
TWI554284B (zh) 2013-04-16 2016-10-21 建南德克公司 帕妥珠單抗（ｐｅｒｔｕｚｕｍａｂ）變體及其評估
US20190307741A1 (en) * 2016-07-06 2019-10-10 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination
CN117752782A (zh) 2017-01-17 2024-03-26 豪夫迈·罗氏有限公司 皮下her2抗体配制剂
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
KR20250151568A (ko) 2020-06-29 2025-10-21 제넨테크, 인크. 퍼투주맙 + 트라스투주맙 고정 용량 조합

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ERMELINDA DE MAIO ET AL.: "Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial", 《BMC CANCER》 *
HAROLD J. BURSTEIN ET AL.: "Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer", 《JOURNAL OF CLINICAL ONCOLOGY》 *
MOHAMMAD JAHANZEB ET AL.: "Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer", 《THE ONCOLOGIST》 *

Also Published As

Publication number Publication date
TW200908976A (en) 2009-03-01
BRPI0812280A2 (pt) 2014-11-18
EP1997534A1 (en) 2008-12-03
TN2009000490A1 (en) 2011-03-31
ZA200908247B (en) 2010-10-27
EP2164573A1 (en) 2010-03-24
AU2008257555A1 (en) 2008-12-04
MX2009012874A (es) 2010-03-31
IL202393A0 (en) 2010-06-30
KR20100017752A (ko) 2010-02-16
NO20093536L (no) 2009-12-16
WO2008145697A1 (en) 2008-12-04
US20100196363A1 (en) 2010-08-05
CA2689664A1 (en) 2008-12-04
CL2008001589A1 (es) 2009-03-06
RU2009146882A (ru) 2011-07-10
JP2010528091A (ja) 2010-08-19
AR066778A1 (es) 2009-09-09

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
ES2904880T3 (es) Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1
CN101687104A (zh) 包括长春氟宁和曲妥单抗的癌症治疗联合疗法
EP3076972B1 (en) Cancer treatment with combination of plinabulin and taxane
CN102770131A (zh) 卡巴他赛的新颖抗肿瘤用途
EP3042669B1 (en) Antitumor agent and antitumor effect enhancer
US11701356B2 (en) Treatment of breast cancer using combination therapies comprising an AKT inhibitor, a taxane, and a PD-L1 inhibitor
JP2009536956A (ja) 抗癌治療法
US11000518B2 (en) Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer
EP4430075A1 (en) Lurbinectedin and atezolizumab combinations
WO2008033041A1 (en) Cancer treatment
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
JP6458007B2 (ja) 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤
TW201306833A (zh) 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合
MXPA06014477A (es) Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer.
JP7450037B2 (ja) 脳転移を有する末期非小細胞肺がん患者を治療するための組み合わせ医薬品
EP4659741A1 (en) Use of paclitaxel cationic liposome in treating tumors
HK1139345A (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
CN102939086B (zh) 胃癌的治疗方法
WO2023111810A1 (en) Combination therapies and uses for treating cancer
HK40054116A (en) Pharmaceutical combination preparation for treating terminal non-small cell lung cancer patients with brain metastasis
CN120826242A (zh) 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途
AU2015200149B2 (en) Novel antitumoral use of cabazitaxel
Modi et al. 7 Development of Inhibitors
Kelly et al. 404 POSTER A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1139345

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100331

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1139345

Country of ref document: HK